Identify Sensors Biologics

A highly accurate, portable, and reusable COVID self-test for smartphones

Purdue University and IdentifySensors Biologics have partnered to create Check4-COVID™: a highly accurate, over-the-counter device intended to detect COVID-19 RNA in minutes in early and asymptomatic infections.

The device uses newly developed nanosensors, saliva, and a smartphone to pinpoint infections in minutes that current tests and home tests miss. It is intended to be sold at pharmacies at $80 for the device and $21 for each test. The system will also detect the new variants of COVID-19. This over-the-counter device is intended to be used entirely at…

Chapters:

1. Disclaimers and Rod’s background
2. Big Picture View
3. Details — Advantages and disadvantages of Reg A+ compared to a conventional SPAC
4. Tripping hazards
5. The two types of IPO methods
6. Underwriters
7. Marketing, Costs, and Timeline
8. Post Reg A+ liquidity — OTC listing
9. Mistakes to Avoid
10. Q&A — Does Manhattan Street Capital help with Marketing?
11. Q&A — How do you think the industry will respond to this use of Reg A+
12. Q&A — Raising money from non-US investors
13. Q&A — Is Debt or Equity more attractive?
14. Q&A — Recommendations to mitigate risk
15. Q&A — Reg A+ vs Reg D
16. Q&A —…

Wednesday, Jan 27th, 11:00 am — 12:15 pm (PST) | 2:00 pm to 3:15 pm (EST)

Sign up for the webinar for free, it only takes 10 seconds.

Sign Up For The Webinar

In this webinar, we will be discussing how to Use Reg A+ for a SPAC Up To $75M To The NASDAQ

We will discuss the following aspects and uses of Reg A+ for your SPAC;

- Advantages of using Reg A+ for your SPAC IPO

- The methods that must be used

- Choice of the method to IPO your SPAC to the NASDAQ

- Underwriter involvement

…

Chapters:

1. Rod’s background
2. About Manhattan Street Capital and Reg A+
3. Webinar Agenda
4. Number of IPOs to date
5. Briefly about Reg A+ (reporting obligations, audit, minimum-maximum amounts, who can invest in a Reg A+ offering, etc)
6. Interesting aspects of Reg A+
7. Downsides of Reg A+
8. Advantages of using Reg A+ to IPO
9. Two approaches to a NASDAQ IPO
10. Timeline Schedule
11. Marketing and Costs
12. Secondary offerings
13. Divisions of large companies
14. Reg A+ Liquidity
15. Mistakes to avoid & Tips and Techniques
16. Q&A — Reg D vs Reg A+
17. Q&A — Breaking down costs
18. Q&A — Reg A+ vs a Reverse Merger with…

Biologx

Biologx Proprietary Technology Rapidly Produces Insulin, at 70% Less Than Current Prices to the Patient

Biologx has devised unique processes for the production of Insulin that enable them to make high-quality insulin in the US at lower cost. Attractive Investment that can save lives.

- 35–40% higher product yield compared to competitors

- 5 times faster production time

- 3 times fewer production steps

- 75% less overhead expenses

Biologx has filed with the SEC to qualify their Reg A+. Make a reservation now to lock in the initial share price.

Reserve now — Minimum reservation $300

Wednesday, Dec 16th, 11:00 am — 12:15 pm (PDT) | 2:00 pm to 3:15 pm (EST)

Sign up for the webinar for free, it only takes 10 seconds

SIGN UP FOR THE WEBINAR

We will discuss the following aspects and uses of Reg A+

- Advantages of using Reg A+ for your IPO

- Choice of method to IPO to the NASDAQ

- Underwriter involvement

- Marketing and costs

- Liquidity for Insiders and early investors

- OTC IPO how and why to take this approach

- What it takes to perform post IPO

- Raising $75 mill for divisions…

FEATURED

The SEC has decided to increase by 50% the maximum offering amount under Tier 2 of Reg A+ from $50 million to $75 million per year, effective 60 days after publication in the Federal Register.

Note that companies that already have Qualified their Reg A+ will be allowed to file a Post Qualification Amendment with the SEC to increase the amount of capital sought in their Reg A+ after the change is effective.

The SEC announcement has caused some confusion by referring to "secondary offerings" being increased from $15 mill to $22.5 mill, because the term "Secondary Offerings" is often…

Edoceo Devices

Building compact and portable test devices to detect COVID-19.

Edoceo is raising $20M with their Reg A+ offering to fast-track development of a testing platform Called V-Detect, their SARS-CoV-2 Virus Test for use in Doctor’s offices, Clinics, and Airports.

- Results in under 30 minutes

- Affordable

- Accurate method that greatly reduces false positive and negative results

- COVID-19 test based on RNA amplification

Anyone can invest — Minimum Investment $580